Company news

Minerva Neurosciences, Inc news in 2021

Minerva Neurosciences, Inc's news releases, calls and decks from 2021, newest first.

View company

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

November 7, 2021

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

November 2, 2021

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

October 31, 2021

Minerva Neurosciences Announces Promotion of Geoff Race to President

October 10, 2021

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

September 29, 2021

Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development

September 7, 2021

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

August 1, 2021

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

May 11, 2021

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

May 10, 2021

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

March 7, 2021

Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021

February 28, 2021

Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million

January 18, 2021

Calls in 2021

Decks in 2021